These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 18780871)

  • 1. Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
    Gurwitz D; Newman W
    J Natl Cancer Inst; 2008 Sep; 100(18):1331; author reply 1332-4. PubMed ID: 18780871
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
    Chlebowski RT; Col N
    J Natl Cancer Inst; 2008 Sep; 100(18):1331-2; author reply 132-3. PubMed ID: 18780870
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
    Punglia RS; Burstein HJ; Winer EP; Weeks JC
    J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
    Rae JM; Drury S; Hayes DF; Stearns V; Thibert JN; Haynes BP; Salter J; Sestak I; Cuzick J; Dowsett M;
    J Natl Cancer Inst; 2012 Mar; 104(6):452-60. PubMed ID: 22395643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of anastrozole in the chemoprevention and treatment of breast cancer: A literature review.
    Barros-Oliveira MDC; Costa-Silva DR; Andrade DB; Borges US; Tavares CB; Borges RS; Silva JM; Silva BBD
    Rev Assoc Med Bras (1992); 2017 Apr; 63(4):371-378. PubMed ID: 28614542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
    Regan MM; Leyland-Jones B; Bouzyk M; Pagani O; Tang W; Kammler R; Dell'orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Neven P; Debled M; Maibach R; Price KN; Gelber RD; Coates AS; Goldhirsch A; Rae JM; Viale G;
    J Natl Cancer Inst; 2012 Mar; 104(6):441-51. PubMed ID: 22395644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer.
    Sanford M; Plosker GL
    Drugs; 2008; 68(9):1319-40. PubMed ID: 18547136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
    Baumann CK; Castiglione-Gertsch M
    Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention.
    Nabholtz JM
    Oncology; 2006; 70(1):1-12. PubMed ID: 16439860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women.
    Nabholtz JM
    Am J Hosp Palliat Care; 2004; 21(6):457-65. PubMed ID: 15612238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
    McKeage K; Curran MP; Plosker GL
    Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment.
    Woods B; Veenstra D; Hawkins N
    Value Health; 2011 Dec; 14(8):989-1001. PubMed ID: 22152167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A decade of letrozole: FACE.
    O'Shaughnessy J
    Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):67-74. PubMed ID: 17912637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
    Jakesz R; Greil R; Gnant M; Schmid M; Kwasny W; Kubista E; Mlineritsch B; Tausch C; Stierer M; Hofbauer F; Renner K; Dadak C; Rücklinger E; Samonigg H;
    J Natl Cancer Inst; 2007 Dec; 99(24):1845-53. PubMed ID: 18073378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
    Pharoah PD; Abraham J; Caldas C
    J Natl Cancer Inst; 2012 Aug; 104(16):1263-4; author reply 1266-8. PubMed ID: 22851268
    [No Abstract]   [Full Text] [Related]  

  • 16. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
    Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J;
    Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only?
    Van Poznak CH; Hayes DF
    J Natl Cancer Inst; 2006 Sep; 98(18):1261-3. PubMed ID: 16985239
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.
    Nakamura Y; Ratain MJ; Cox NJ; McLeod HL; Kroetz DL; Flockhart DA
    J Natl Cancer Inst; 2012 Aug; 104(16):1264; author reply 1266-8. PubMed ID: 22851270
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.
    Stanton V
    J Natl Cancer Inst; 2012 Aug; 104(16):1265-6; author reply 1266-8. PubMed ID: 22851267
    [No Abstract]   [Full Text] [Related]  

  • 20. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
    van Nes JG; Seynaeve C; van de Velde CJ; Nortier JW
    Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2863-9. PubMed ID: 17319217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.